We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01015144
Recruitment Status : Completed
First Posted : November 18, 2009
Last Update Posted : November 18, 2009
Sponsor:
Information provided by:

November 17, 2009
November 18, 2009
November 18, 2009
February 2007
December 2008   (Final data collection date for primary outcome measure)
left ventricular function [ Time Frame: 2 months ]
Same as current
No Changes Posted
mortality [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle
The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy
The aim of the study was to assess of the influence of atorvastatin on selected indicators of an inflammatory condition, function of the left ventricle and factors affecting the occurrence of undesired events like rehospitalizations and mortality in patients with dilated cardiomyopathy.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
blood68
Probability Sample
Patients with dilated cardiomyopathy (according ESC 2007) with EF≤40% as documented by echocardiography were included.
Dilated Cardiomyopathy
Drug: Tulip
Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
  • Atorvastatin
    Intervention: Drug: Tulip
  • No statin

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
February 2009
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients 18 years old or older
  • patients who signed informed consent
  • patients with dilated cardiomyopathy (according ESC 2007)
  • patients who had no significant coronary artery stenoses >30% on cardiac catheterization

Exclusion Criteria:

  • BP ≥140/90 lub <90/60
  • congenital heart disease
  • acquired valvular disease except for mitral incompetence secondary to left ventricular dilatation
  • New York Heart Association (NYHA) functional class IV
  • statin treatment
  • preserved hyperactivity of aminotransferases with unexplained etiology,
  • muscle disorders which might cause drug-induced myopathy,
  • uncontrolled diabetes,
  • liver diseases,
  • creatinine level > 2 mg/dl and/or GFR<30ml/min,
  • abuse of alcohol or drugs,
  • chronic inflammatory diseases,
  • pregnancy or lactation,
  • severe hypothyroidism,
  • immunosuppressive treatment,
  • operation or severe injury during last month
  • vaccination during last 3 months
  • heart stimulation device or implantable cardioverter defibrillator
  • or who didn't write conscious consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01015144
502-11-585
Yes
Not Provided
Not Provided
Agata Bielecka-Dąbrowa, UM Lodz
Medical Universtity of Lodz
Not Provided
Principal Investigator: Agata Bielecka-Dabrowa, PhD Department of Hypertension UM Lodz
Study Director: Maciej Banach, Assoc. Prof. Department of Hypertension UM Lodz
Medical Universtity of Lodz
November 2009